- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Endocrinology
Volume 2013 (2013), Article ID 197519, 6 pages
Association between Osteocalcin, Metabolic Syndrome, and Cardiovascular Risk Factors: Role of Total and Undercarboxylated Osteocalcin in Patients with Type 2 Diabetes
1Obesity Research Center, College of Medicine, King Saud University, P.O. Box 2925 (98), Riyadh 11461, Saudi Arabia
2Department of Medicine, College of Medicine, King Saud University, P.O. Box 2925 (38), Riyadh 11461, Saudi Arabia
3Department of Family and Community Medicine, College of Medicine, King Saud University, P.O. Box 2925, Riyadh 11461, Saudi Arabia
4Department of Preventive Medicine, University of Southern California, Los Angeles, CA 90089, USA
Received 5 December 2012; Revised 13 March 2013; Accepted 13 March 2013
Academic Editor: Mario Maggi
Copyright © 2013 Assim A. Alfadda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. Tan, Y. Gao, X. Yang et al., “Low serum osteocalcin level is a potential marker for metabolic syndrome: results from a Chinese male population survey,” Metabolism, vol. 60, no. 8, pp. 1186–1192, 2011.
- U. Saleem, T. H. Mosley Jr., and I. J. Kullo, “Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 7, pp. 1474–1478, 2010.
- J. Gomez-Ambrosi, A. Rodriguez, V. Catalan, et al., “The bone-adipose axis in obesity and weight loss,” Obesity Surgery, vol. 18, no. 9, pp. 1134–1143, 2008.
- A. J. Lee, S. Hodges, and R. Eastell, “Measurement of osteocalcin,” Annals of Clinical Biochemistry, vol. 37, pp. 432–446, 2000.
- N. K. Lee, H. Sowa, E. Hinoi, et al., “Endocrine regulation of energy metabolism by the skeleton,” Cell, vol. 130, no. 3, pp. 456–469, 2007.
- M. Ferron, E. Hinoi, G. Karsenty, and P. Ducy, “Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5266–5270, 2008.
- D. Benayahu, A. Shamay, and S. Wientroub, “Osteocalcin (BGP), gene expression, and protein production by marrow stromal adipocytes,” Biochemical and Biophysical Research Communications, vol. 231, no. 2, pp. 442–446, 1997.
- M. A. Thiede, S. L. Smock, D. N. Petersen, W. A. Grasser, D. D. Thompson, and S. K. Nishimoto, “Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripheral blood platelets,” Endocrinology, vol. 135, no. 3, pp. 929–937, 1994.
- S. H. Kim, J. W. Lee, J. A. Im, and H. J. Hwang, “Serum osteocalcin is related to abdominal obesity in Korean obese and overweight men,” Clinica Chimica Acta, vol. 411, no. 23-24, pp. 2054–2057, 2010.
- J. M. Kindblom, C. Ohlsson, O. Ljunggren et al., “Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men,” Journal of Bone and Mineral Research, vol. 24, no. 5, pp. 785–791, 2009.
- M. K. Shea, C. M. Gundberg, J. B. Meigs et al., “γ-carboxylation of osteocalcin and insulin resistance in older men and women,” American Journal of Clinical Nutrition, vol. 90, no. 5, pp. 1230–1235, 2009.
- I. Kanazawa, T. Yamaguchi, M. Yamauchi et al., “Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus,” Osteoporosis International, vol. 22, no. 1, pp. 187–194, 2011.
- M. Iki, J. Tamaki, Y. Fujita et al., “Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study,” Osteoporosis International, vol. 23, no. 2, pp. 761–770, 2012.
- W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972.
- S. M. Grundy, “United States cholesterol guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy,” American Journal of Cardiology, vol. 88, no. 7B, pp. 23J–27J, 2001.
- I. Kanazawa, T. Yamaguchi, Y. Tada, M. Yamauchi, S. Yano, and T. Sugimoto, “Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes,” Bone, vol. 48, no. 4, pp. 720–725, 2011.
- A. G. Pittas, S. S. Harris, M. Eliades, et al., “Association between serum osteocalcin and markers of metabolic phenotype,” Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 3, pp. 827–832, 2009.
- A. D. Sniderman, “Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thing,” Diabetes Care, vol. 26, no. 7, pp. 2207–2208, 2003.
- G. Walldius and I. Jungner, “Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy,” Journal of Internal Medicine, vol. 255, no. 2, pp. 188–205, 2004.
- J. Sierra-Johnson, V. K. Somers, F. H. S. Kuniyoshi et al., “Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome,” American Journal of Cardiology, vol. 98, no. 10, pp. 1369–1373, 2006.
- G. Walldius, I. Jungner, I. Holme, A. H. Aastveit, W. Kolar, and E. Steiner, “High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study,” The Lancet, vol. 358, no. 9298, pp. 2026–2033, 2001.
- L. E. Polgreen, D. R. Jacobs, B. M. Nathan, et al., “Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults,” Obesity, vol. 20, no. 11, pp. 2194–2201, 2012.
- B. B. Yeap, S. A. Chubb, L. Flicker, et al., “Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study,” Osteoporosis International, vol. 23, no. 2, pp. 599–606, 2012.
- M. M. Oosterwerff, N. M. van Schoor, P. Lips, et al., “Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study,” Clinical Endocrinology, vol. 78, no. 2, pp. 242–247, 2013.